Abstract
Although several constitutive proteasome inhibitors have been reported these recent years, potent organic, noncovalent and readily available inhibitors are still poorly documented. Here we used a structure- and ligand-based in silico approach to identify commercially available 1,2,4-oxadiazole derivatives as non-covalent human 20S proteasome inhibitors. Their optimization led to the newly synthesized compound 4h that is a mixed proteasomal inhibitor of the chymotrypsin- like activity (Ki of 26,1 nM and K’i of 7.5 nM) which is in addition selective versus the challenging cathepsin B and calpain proteases. Molecular modelling studies corroborated the mechanism of inhibition and suggest an unusual binding of the inhibitor within the S5 binding pocket (β6 subunit). The cellular effects of our compounds validate their utility as potential pharmacological agents for anti-cancer pre-clinical studies.
Keywords: Chymotrypsin-like subsite S5 binding, cytotoxicity, non-covalent inhibitors, oxadiazoles, proteasome, virtual screening.
Current Medicinal Chemistry
Title:1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome
Volume: 20 Issue: 18
Author(s): X. Maréchal, E. Genin, L. Qin, O. Sperandio, M. Montes, N. Basse, N. Richy, M.A. Miteva, M. Reboud-Ravaux, J. Vidal and B.O. Villoutreix
Affiliation:
Keywords: Chymotrypsin-like subsite S5 binding, cytotoxicity, non-covalent inhibitors, oxadiazoles, proteasome, virtual screening.
Abstract: Although several constitutive proteasome inhibitors have been reported these recent years, potent organic, noncovalent and readily available inhibitors are still poorly documented. Here we used a structure- and ligand-based in silico approach to identify commercially available 1,2,4-oxadiazole derivatives as non-covalent human 20S proteasome inhibitors. Their optimization led to the newly synthesized compound 4h that is a mixed proteasomal inhibitor of the chymotrypsin- like activity (Ki of 26,1 nM and K’i of 7.5 nM) which is in addition selective versus the challenging cathepsin B and calpain proteases. Molecular modelling studies corroborated the mechanism of inhibition and suggest an unusual binding of the inhibitor within the S5 binding pocket (β6 subunit). The cellular effects of our compounds validate their utility as potential pharmacological agents for anti-cancer pre-clinical studies.
Export Options
About this article
Cite this article as:
Maréchal X., Genin E., Qin L., Sperandio O., Montes M., Basse N., Richy N., Miteva M.A., Reboud-Ravaux M., Vidal J. and Villoutreix B.O., 1,2,4-Oxadiazoles Identified by Virtual Screening and their Non-Covalent Inhibition of the Human 20S Proteasome, Current Medicinal Chemistry 2013; 20 (18) . https://dx.doi.org/10.2174/0929867311320180006
DOI https://dx.doi.org/10.2174/0929867311320180006 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Why Some Messages Speak Better: Child Immunization in the News and on the Internet
Current Drug Safety Identification of Novel Small-Molecule ASGP-R Ligands
Current Drug Delivery Synthesis and Structure Activity Relationship Study of N-substituted 3,5-diarylidenepiperidin- 4-ones as Potential Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Interactions of Dietary Flavonoids with Proteins: Insights from Fluorescence Spectroscopy and Other Related Biophysical Studies
Current Drug Metabolism The Potent Inhibitory Effect of β-D-Mannuronic Acid (M2000) as a Novel NSAID with Immunosuppressive Property on Anti-Cyclic Citrullinated Peptide Antibodies, Rheumatoid Factor and Anti-dsDNA Antibodies in Patients with Rheumatoid Arthritis
Current Drug Discovery Technologies Regulatory Roles of Amino Acids in Immune Response
Current Rheumatology Reviews Current Prevention and Treatment of Postoperative Nausea and Vomiting after Gynecological Laparoscopic Surgery
Current Drug Therapy Meet Our Editor
Current Metabolomics Nasal Drug Delivery System-Factors Affecting and Applications
Current Drug Therapy Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Structure-Activity Relationships of Multidrug Resistance Reversers
Current Medicinal Chemistry Mechanisms Used by Human Papillomaviruses to Escape the Host Immune Response
Current Cancer Drug Targets Disorder in Milk Proteins: Caseins, Intrinsically Disordered Colloids
Current Protein & Peptide Science 20 Years of Lipid Nanoparticles (SLN & NLC): Present State of Development & Industrial Applications
Current Drug Discovery Technologies Toxicological Effects of Dietary Biogenic Amines
Current Nutrition & Food Science Ultrasound Enhances the Transfection of Plasmid DNA by Non-viral Vectors
Current Pharmaceutical Biotechnology Therapeutic Antibodies and Other Proteins Obtained by Molecular Display Technologies
Recent Patents on Biotechnology Evaluation of In-Vitro Multidrug Resistance Reversal Activities of HZ08 analogues with Improved Soluble Property
Letters in Drug Design & Discovery Nanostructures as Promising Tools for Delivery of Antimicrobial Peptides
Mini-Reviews in Medicinal Chemistry Organic/Inorganic Hybrid Functionalized Magnetic Nanoparticles for High Throughput Biomolecular Separation
Current Organic Chemistry